The Best Investment You Didn’t Know You Made:
Honored to have our work on the NIH contribution to drug approvals cited
jamanetwork.com/journals/jam...
www.amfar.org/wp-content/u...

Equity investment in #Biotechnology increased in the six quarters after passage of #InflationReductionAct, stabilizing above pre-pandemic levels. This shows robust investment in #innovation despite potential future price reductions. Read research here: www.sciencedirect.com/science/arti...

Love the microflier from @standupforscience.bsky.social
www.standupforscience.net Please share
Read the original research @jamahealthforum.bsky.social jamanetwork.com/journals/jam...

www.amfar.org/wp-content/u...
Honored to have our work on the NIH contribution to new drug approvals referenced by @amfarofficial.bsky.social. Read the original research here.https://jamanetwork.com/journals/jama-health-forum/fullarticle/2804378

The @nytimes.com today published a graphic illustrating data cited in this commentary on the essential role of the NIH in new drug approvals. The original study was also in @jamahealthforum.bsky.social jamanetwork.com/journals/jam... @ineteconomics.bsky.social @bentley-university.bsky.social

#ResearchSavesLives Original research published
@jamahealthforum.bsky.social jamanetwork.com/journals/jam... @ineteconomics.bsky.social
@bentleyuniv.bsky.social Research Saves Lives site by
@johnshopkinssph.bsky.social

#R&D by industry has different role than #R&D funded by government. These comparisons are from the National Center for Science and Engineering Statistics @ncse.bsky.social. Federal funding is essential for the #basicresearch and #appliedresearch that drives #innovation ncses.nsf.gov/pubs/nsf25327

Philanthopy definitely matters, but is a very small fraction of capital available for R&D in the US. These data are from the National Science & Technology Indicators (2025) and describes all fields of science, not biomedical science of biopharmaceuticals. ncses.nsf.gov/data-collect...

NIH funds ~$1.4 billion in basic or applied research contributing to each new drug approval, enabling drug discovery and development and reducing industry's investment in each new drug by half. jamanetwork.com/journals/jam...
@bentley-university.bsky.social, @ineteconomics.bsky.social
@cnbc.com

Our 2023 JAMA HF study was featured on CNBC as John Flavin, Portal Innovations Founder & CEO, discussed how NIH funding cuts could be detrimental for the U.S. pharmaceutical industry and drug development. Our study found that the NIH provided funding for 354/356 drugs approved by the FDA 2010-19.